RSLS Stock Price: Understanding ReShape Lifesciences' Transition
ReShape Lifesciences Inc. (RSLS) Overview
ReShape Lifesciences Inc., formerly traded under the ticker RSLS, was a prominent medical device company focused on providing minimally invasive technologies for treating obesity and metabolic diseases. Based on reports as of mid-2025, the company has undergone a fundamental structural change, moving from a standalone entity to a part of a larger healthcare conglomerate through a strategic merger.
For investors tracking the rsls stock price, it is crucial to understand that the ticker symbol has transitioned. Following a merger with Vyome Therapeutics, the company now operates under the umbrella of Vyome Holdings with the new ticker symbol HIND on the NASDAQ exchange.
Stock Performance and Price History
Historical Price Trends
The rsls stock price has been characterized by significant volatility over its final trading years. According to data from Robinhood and Stock Analysis, the stock saw a 52-week range fluctuating between a low of $0.11 and a high of $0.67 during its active period. At the time of its final valuation before the ticker change, the price sat near $15.68 following technical adjustments.
Market Capitalization and Valuation
As of its last major reporting period in August 2025, the market capitalization for the entity reached approximately $478.45 million. The enterprise value remained a key metric for analysts, reflecting the total value of the business including debt and cash reserves. In the healthcare sector, ReShape was often compared to peer medical device firms specializing in bariatric solutions.
Reverse Stock Splits
To maintain compliance with NASDAQ’s minimum bid price requirements, ReShape Lifesciences implemented several reverse stock splits. Notably, actions were taken in September 2024 and again in August 2025. These splits adjusted the rsls stock price upward by reducing the number of shares outstanding, a common move for micro-cap companies facing delisting pressures.
Financial Metrics
Revenue and Earnings
Financial disclosures from ADVFN indicate that ReShape Lifesciences reported annual revenues of approximately $8.01 million. Despite consistent revenue streams from its core products, the company faced net income losses typical of high-growth medical technology firms. The Earnings Per Share (EPS) remained under scrutiny as the company prioritized market expansion over immediate profitability.
Balance Sheet and Liquidity
Prior to its merger, the company maintained a balance sheet focused on supporting its clinical trials and commercialization efforts. Key metrics included a total of 11.28 million shares outstanding. Analysts monitored the current ratio closely to ensure the company had enough liquidity to cover short-term liabilities during its transition to the new corporate structure.
Product Portfolio and Technology
Lap-Band® System
The flagship product of ReShape Lifesciences was the Lap-Band® System. This is an FDA-approved, minimally invasive gastric banding device designed for long-term weight loss. It stood as a leader in the industry for patients seeking alternatives to more invasive stapling procedures.
Pipeline and Developmental Assets
Beyond the Lap-Band, the company developed the Obalon® Balloon System, the first swallowable, gas-filled intragastric balloon. They also advanced the Diabetes Bloc-Stim Neuromodulation (DBSN) device, which aims to treat type 2 diabetes by modulating the vagus nerve signals.
Corporate Mergers and Acquisitions
Merger with Vyome Therapeutics
The most significant event affecting the rsls stock price was the 2025 merger with Vyome Therapeutics. According to Stock Titan, this was a reverse merger that resulted in the formation of Vyome Holdings. Effective August 15, 2025, RSLS was delisted, and the new entity began trading under the ticker HIND.
Asset Sale to Biorad Medisys
As part of the merger agreement, ReShape Lifesciences sold substantially all of its physical assets and product lines to Biorad Medisys. This strategic move allowed the newly formed Vyome Holdings to focus on immuno-inflammatory disease treatments while ensuring the continued availability of ReShape's bariatric technologies under new ownership.
Market Sentiment and Analyst Ratings
During its final months of trading, institutional ownership of RSLS stood at approximately 8.5%. Short interest levels remained moderate as traders speculated on the outcome of the merger. Most market analysts maintained a "Hold" rating, reflecting the uncertainty and high-risk nature of clinical-stage medical device companies during reorganization.
Exploring Global Financial Trends with Bitget
While the rsls stock price transition represents a major shift in the traditional medical equity market, many investors are increasingly looking toward diversified assets. Understanding market volatility and corporate transitions is a vital skill whether you are trading NASDAQ stocks or exploring the digital asset space.
If you are interested in expanding your portfolio beyond traditional stocks, Bitget offers a secure platform to explore a wide range of financial opportunities. By staying informed on both equity mergers and emerging digital trends, you can make more balanced decisions in an ever-evolving global economy.
